Enhabit, Inc. (NYSE:EHAB) Sees Significant Increase in Short Interest

Enhabit, Inc. (NYSE:EHAB) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,290,000 shares, a growth of 6.6% from the November 30th total of 1,210,000 shares. Approximately 2.9% of the shares of the stock are short sold. Based on an average trading volume of 412,800 shares, the short-interest ratio is currently 3.1 days.

Enhabit Trading Up 1.6 %

NYSE EHAB opened at $7.81 on Thursday. The firm has a market capitalization of $392.72 million, a PE ratio of -3.37 and a beta of 1.89. The stock’s 50 day moving average is $7.72 and its 200 day moving average is $8.18. Enhabit has a twelve month low of $6.85 and a twelve month high of $11.74. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85.

Enhabit (NYSE:EHAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to the consensus estimate of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter last year, the firm posted $0.03 EPS. Research analysts forecast that Enhabit will post 0.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Enhabit

In related news, Director Stuart M. Mcguigan bought 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the acquisition, the director now directly owns 46,810 shares of the company’s stock, valued at $412,396.10. The trade was a 47.15 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bolton acquired 4,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $8.69 per share, with a total value of $34,760.00. Following the transaction, the director now directly owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. The trade was a 4.25 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Enhabit

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC boosted its position in shares of Enhabit by 138.4% in the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock worth $27,000 after purchasing an additional 1,967 shares in the last quarter. Quarry LP raised its stake in Enhabit by 242.2% during the second quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after buying an additional 2,621 shares during the last quarter. Gladius Capital Management LP boosted its holdings in Enhabit by 78.2% in the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after acquiring an additional 2,747 shares in the last quarter. Stoneridge Investment Partners LLC purchased a new stake in shares of Enhabit in the third quarter worth $81,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Enhabit during the second quarter valued at $93,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and increased their price objective for the stock from $8.25 to $9.50 in a report on Monday, December 9th. Leerink Partners reissued a “market perform” rating and set a $8.00 price objective (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.75.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.